2 weeks Ago By ABMN Staff
American Century Companies Inc. lifted its holdings in shares of Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 122,096 shares of the company’s stock after buying an additional 4,757 shares during the period. American Century Companies Inc.’s holdings in Elanco Animal Health were worth $1,762,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ELAN. ORG Partners LLC bought a new stake in shares of Elanco Animal Health during the 2nd quarter valued at $31,000. nVerses Capital LLC bought a new position in Elanco Animal Health in the 2nd quarter valued at $32,000.
Jones Financial Companies Lllp purchased a new position in shares of Elanco Animal Health during the fourth quarter worth approximately $37,000. Global Financial Private Client LLC purchased a new position in shares of Elanco Animal Health during the first quarter valued at $72,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in Elanco Animal Health during the second quarter valued at approximately $158,000.
Institutional investors own 97.48% of the company’s stock. Elanco Animal Health Trading Up 4.
3 % NYSE ELAN opened at $14.32 on Monday. Elanco Animal Health Incorporated has a 12-month low of $8.
52 and a 12-month high of $18.80. The company has a fifty day simple moving average of $14.
05 and a two-hundred day simple moving average of $15.07. The company has a current ratio of 2.
93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92.
The stock has a market cap of $7.08 billion, a P/E ratio of -5.40, a P/E/G ratio of 1.
33 and a beta of 1.40. Insider Buying and Selling at Elanco Animal Health In other Elanco Animal Health news, Director Michael J.
Harrington bought 3,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, with a total value of $51,975.
00. Following the completion of the acquisition, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the business’s stock in a transaction on Monday, August 12th.
The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00.
Following the completion of the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, Director Michael J.
Harrington bought 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.
00. Following the completion of the purchase, the director now owns 81,094 shares in the company, valued at $1,204,245.90.
The disclosure for this purchase can be found here . Company insiders own 0.57% of the company’s stock.
Analyst Upgrades and Downgrades Several research firms have commented on ELAN. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research report on Thursday, September 19th.
Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $17.00 to $15.00 in a research report on Thursday, September 19th.
Piper Sandler cut their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st.
Finally, Barclays upped their price target on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd.
One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.43.
Get Our Latest Research Report on ELAN About Elanco Animal Health ( Free Report ) Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. Further Reading Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.
com's FREE daily email newsletter ..
